Table of Contents Author Guidelines Submit a Manuscript
Case Reports in Nephrology
Volume 2015, Article ID 512549, 3 pages
http://dx.doi.org/10.1155/2015/512549
Case Report

A Case of Nephrotic Syndrome, Showing Evidence of Response to Saquinavir

1Department of Renal Medicine, Canberra Hospital, Garran, ACT 2605, Australia
2Australian National University Medical School, Canberra, Australia
3The Canberra Hospital, Australia

Received 24 September 2014; Revised 6 January 2015; Accepted 11 January 2015

Academic Editor: Patrick Honoré

Copyright © 2015 Giles Walters et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. S. G. Deeks, M. Smith, M. Holodniy, and J. O. Kahn, “HIV-1 protease inhibitors: a review for clinicians,” Journal of the American Medical Association, vol. 277, no. 2, pp. 145–153, 1997. View at Publisher · View at Google Scholar · View at Scopus
  2. S. G. Deeks and P. A. Volberding, “HIV-1 protease inhibitors,” AIDS Clinical Review, pp. 145–185, 1997. View at Google Scholar · View at Scopus
  3. R. Valle and L. Haragsim, “Nephrotoxicity as a complication of antiretroviral therapy,” Advances in Chronic Kidney Disease, vol. 13, no. 3, pp. 314–319, 2006. View at Publisher · View at Google Scholar · View at Scopus
  4. S. H. Lecker and W. E. Mitch, “Proteolysis by the ubiquitin-proteasome system and kidney disease,” Journal of the American Society of Nephrology, vol. 22, no. 5, pp. 821–824, 2011. View at Publisher · View at Google Scholar · View at Scopus
  5. M. Piccinini, M. T. Rinaudo, A. Anselmino et al., “The HIV protease inhibitors nelfinavir and saquinavir, but not a variety of HIV reverse transcriptase inhibitors, adversely affect human proteasome function,” Antiviral Therapy, vol. 10, no. 2, pp. 215–223, 2005. View at Google Scholar · View at Scopus
  6. J. van der Vlag and J. H. M. Berden, “Proteasome inhibition: a new therapeutic option in lupus nephritis?” Nephrology Dialysis Transplantation, vol. 23, no. 12, pp. 3771–3772, 2008. View at Publisher · View at Google Scholar · View at Scopus
  7. C. Cao, S. Lu, C. Dong, and R. Zhao, “Abnormal DNA-binding of transcription factors in minimal change nephrotic syndrome,” Pediatric Nephrology, vol. 16, no. 10, pp. 790–795, 2001. View at Publisher · View at Google Scholar · View at Scopus
  8. D. Sahali, A. Pawlak, S. Le Gouvello et al., “Transcriptional and post-transcriptional alterations of IκBα in active minimal-change nephrotic syndrome,” Journal of the American Society of Nephrology, vol. 12, no. 8, pp. 1648–1658, 2001. View at Google Scholar · View at Scopus
  9. H. Mansour, L. Cheval, J.-M. Elalouf et al., “T-cell transcriptome analysis points up a thymic disorder in idiopathic nephrotic syndrome,” Kidney International, vol. 67, no. 6, pp. 2168–2177, 2005. View at Publisher · View at Google Scholar · View at Scopus
  10. R. Coppo, R. Camilla, M. G. Porcellini et al., “Saquinavir in steroid-dependent and -resistant nephrotic syndrome: a pilot study,” Nephrology Dialysis Transplantation, vol. 27, no. 5, pp. 1902–1910, 2012. View at Publisher · View at Google Scholar · View at Scopus
  11. H. Izzedine, V. Launay-Vacher, A. Baumelou, and G. Deray, “Antiretroviral and immunosuppressive drug-drug interactions: an update,” Kidney International, vol. 66, no. 2, pp. 532–541, 2004. View at Publisher · View at Google Scholar · View at Scopus
  12. R. F. Ransom, N. G. Lam, M. A. Hallett, S. J. Atkinson, and W. E. Smoyer, “Glucocorticoids protect and enhance recovery of cultured murine podocytes via actin filament stabilization,” Kidney International, vol. 68, no. 6, pp. 2473–2483, 2005. View at Publisher · View at Google Scholar · View at Scopus
  13. R. F. Ransom, V. Vega-Warner, W. E. Smoyer, and J. Klein, “Differential proteomic analysis of proteins induced by glucocorticoids in cultured murine podocytes,” Kidney International, vol. 67, no. 4, pp. 1275–1285, 2005. View at Publisher · View at Google Scholar · View at Scopus
  14. S. Meyer, N. G. Kohler, and A. Joly, “Cyclosporine A is an uncompetitive inhibitor of proteasome activity and prevents NF-κB activation,” FEBS Letters, vol. 413, no. 2, pp. 354–358, 1997. View at Publisher · View at Google Scholar · View at Scopus